| Identification | Back Directory | [Name]
BMS707035 | [CAS]
729607-74-3 | [Synonyms]
CS-455
BMS707035
BMS707035 USP/EP/BP
BMS 707035;BMS707035
2-(1,1-DIOXOTHIAZINAN-2-YL)-N-[(4-FLUOROPHENYL)METHYL]-5-HYDROXY-1-METHYL-6-OXOPYRIMIDINE-4-CARBOXAMIDE
4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin
N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-4-pyrimidinecarboxamide
4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)- | [Molecular Formula]
C17H19FN4O5S | [MDL Number]
MFCD18074518 | [MOL File]
729607-74-3.mol | [Molecular Weight]
410.42 |
| Chemical Properties | Back Directory | [density ]
1.54 | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥41 mg/mL in DMSO | [form ]
Powder | [pka]
4.50±1.00(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Uses]
BMS-707035 is a specific HIV-I integrase (IN) inhibitor. | [in vivo]
BMS-707035 has a low clearance effect in the rat, dog and monkey with moderate to long elimination half-lives in all species[1].
Pharmacokinetic Parameters of BMS-707035 in rat, dog and monkey (IV)[1].
| Rat | Monkey | Dog | | IV dose (mg/kg) | 0.87 | 1 | 1 | | CL (ml/min/kg) | 9.7 | 6.8 | 2.0 | | T1/2(h) | 4.0 | 6.5 | 6.0 | | Vss(L/kg) | 0.86 | 0.87 | 0.45 | | PO dose (mg/kg) | 4.4 | 5 | 5.2 | | Cmax(μM) | 4.51 | 6.12 | 72.8 | | tmax(h) | 0.25 | 0.25 | 0.25 | | AUC (μM*h) | 19.1 | 19.2 | 162 | | F (%) | 86 | 56 | 129 | |
| [target]
HIV-I integrase |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|